Eupraxia’s November 3 report is expected to show another quarterly loss. Investors will also be looking for useful context ahead of interim trial data expected later this quarter.
Eupraxia Pharmaceuticals Inc. (EPRX.TO) plans to report results for the quarter ended September 30, 2026, after markets close on November 3. The current EPS consensus is a loss of C$0.33 per share, based on estimates from eight analysts. Those estimates range from a loss of C$0.42 to C$0.29. A separate earnings calendar lists a loss of C$0.26, so the available sources don’t agree on the consensus figure.
Recent earnings trend
Eupraxia Pharmaceuticals Inc
EPRX.TO
EPRX.TO
Eupraxia Pharmaceuticals Inc
WealthAwesomeMarket cap
$629.02M
52W high
$13.08
52W low
$7.35
1W change
-4.79%
Beta
1.22
Analyst Price Targets
Based on analyst covering EPRX · as of Sep 28, 2026
Wall Street analysts forecast EPRX stock price to rise 125.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$16.33
+125.3% Upside
Previously C$16.00 on Sep 17, 2026
Current Price
C$7.25
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EPRX's historical volatility
30-Day Vol
87.0%
Annualized
90-Day Vol
74.4%
Annualized
Trend (90d)
+20.3%
Annualized drift
90d Mean
C$10.24
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.75 | C$7.22 – C$13.17 |
| 60 trading days | C$9.99 | C$6.54 – C$15.27 |
| 90 trading days | C$10.24 | C$6.09 – C$17.21 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 8 analyst(s) cover this name; upcoming EPS consensus is available.
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-03 | — | -0.2600 | — |
| 2026-06-30 | 2026-08-11 | -0.3200 | -0.3200 | +0.0% |
| 2026-03-31 | 2026-05-07 | -0.3201 | -0.1900 | -68.5% |
| 2025-12-31 | 2026-03-12 | -0.5000 | -0.2200 | -127.3% |
| 2025-09-30 | 2025-11-04 | -0.2700 | -0.2700 | +0.0% |
| 2025-06-30 | 2025-08-12 | -0.3600 | -0.2500 | -44.0% |
Eupraxia has matched or missed estimates in each of its last four reported quarters, with no beats. As a clinical-stage biotech, the earnings report is only part of the story. Investors will also be watching for updates on EP-104GI and interim data from its Phase 2b trial, expected in Q4.
Investor takeaway: The available estimates point to another loss, and recent results offer no track record of beating expectations. For Canadian investors, the cash and operating update, along with any trial news, may matter more than a small difference in EPS. Eupraxia expects interim Phase 2b data for EP-104GI in Q4 2026, but the available earnings calendar doesn’t confirm that the data will be released with the November 3 report.
C$0.33 loss per share
Eight analysts expect a loss of C$0.33 per share for the quarter ended September 30, with estimates ranging from C$0.42 to C$0.29 in losses. Another earnings calendar lists a loss of C$0.26. Investors should check the company’s release and updated data to resolve the difference. EPS was a loss of C$0.27 a year ago, while the trend feed forecasts EPS growth of -24.4%.
Bull case
The EPS consensus has improved slightly over the past 30 days, moving from a loss of C$0.34 to C$0.33. One analyst revised their estimate upward, and none revised theirs downward.
Eupraxia has also reported progress on EP-104GI. It reached its target of 120 patients enrolled in the blinded portion of the RESOLVE Phase 2b trial, with interim data expected in Q4. The company has reported 52-week remission observations in a small group of patients. These early findings may draw interest, but they don’t replace results from larger, controlled trials.
Bear case
Eupraxia is still losing money. Its trailing 12-month EPS is -C$1.37, and its reported profit margin is 0.00%. The company has not beaten estimates in its last four comparable quarters, including a 68.47% miss in March 2026 and a 127.27% miss in December 2025.
Analysts still expect a loss. And, as with any biotech, trial results could disappoint, take longer than expected, or fail to show that the treatment works. The reported long-term remission observations came from small groups, so they should be viewed cautiously.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
